Intestinal and hepatic effects of iron oxide nanoparticles

Linn Voss1 · Elisa Hoché1 · Valerie Stock1 · Linda Böhmert1 · Albert Braeuning1 · Andreas F. Thünemann2 · Holger Sieg1

Received: 25 October 2020 / Accepted: 26 November 2020 / Published online: 8 February 2021
© The Author(s) 2021

Abstract
Iron oxide nanoparticles gain increasing attention due to their broad industrial use. However, safety concerns exist since their effects on human cells are still under investigation. The presence of iron oxide nanoparticles in the food pigment E172 has been shown recently. Here, we studied four iron oxide nanoparticles, one food pigment E172 and the ionic control FeSO4 regarding dissolution in biological media, uptake and transport, and cellular effects in vitro in human intestinal Caco-2 and HepaRG hepatocarcinoma cells. The iron oxide nanoparticles passed the gastrointestinal passage without dissolution and reached the intestine in the form of particles. Minor uptake was seen into Caco-2 cells but almost no transport to the basolateral site was detected for any of the tested particles. HepaRG cells showed higher particle uptake. Caco-2 cells showed no alterations in reactive oxygen species production, apoptosis, or mitochondrial membrane potential, whereas two particles induced apoptosis in HepaRG cells, and one altered mitochondrial membrane potential at non-cytotoxic concentrations. No correlation between physicochemical particle characteristics and cellular effects was observed, thus emphasizing the need for case-by-case assessment of iron oxide nanoparticles.

Keywords Nanoparticles · Toxicity · Iron oxide nanoparticles · Uptake and transport · Cellular effects

Introduction
Iron oxide nanoparticles are widely used chemicals. They can be found in the biomedical sector as well as in the food pigment E172 (Vangijzegem et al. 2019; Voss et al. 2020a). Moreover, they were suggested to be suitable for the fortification or iron supplementation of foods: iron oxide nanoparticles are believed to cause less gastrointestinal side effects than ferrous sulphate or gluconate, fewer changes to food texture and taste, and may have a higher bioavailability than their bulk counterparts (Hilty et al. 2010; Hosny et al. 2015; Tolkien et al. 2015). However, the growing use of iron oxide nanoparticles has raised concerns regarding their safety and data on their toxicological potential are still incomplete. Especially uptake, distribution and toxic effects still require investigation.

Nanoparticles can be highly influenced by their chemical environment. When they are taken up orally, they travel through the gastrointestinal passage, where they are in contact with different fluids, varying in pH values and composition. Other nanoparticles such as zinc oxide, silver, and aluminum are strongly affected by the digestion procedure (Kästner et al. 2017; Sieg et al. 2017; Voss et al. 2020b), whereas data about physico-chemical changes during the digestive process are lacking. Especially the acidic stomach juice may lead to dissolution of the nanoparticles and thereby a release of ionic iron. This ionic iron interacts differently with the cellular machinery; uptake and transport mechanisms can differ tremendously between particles and dissolved ions. While divalent iron ions can be taken up via the Divalent Metal Transporter 1 (DMT1), nanoparticles containing iron are believed to be taken up by endocytosis (Zanella et al. 2017). Moreover, many studies investigating the effect of iron oxide nanoparticles on human cells are conducted in vitro. Therefore, the nanoparticles are dispersed in cell culture medium. To ensure the suitability of the test system, it is decisive to know the ion release of iron nanoparticles.
oxide nanoparticles in the respective medium compared to the ion release in the digestive tract.

When taken up orally, the intestinal wall plays a crucial role in the systemic uptake of nanoparticles. Even though animal studies have shown that iron levels rise in downstream organs such as the liver after oral treatment with iron oxide nanoparticles, their effect on hepatic and intestinal cells is still not understood (Singh et al. 2013; Chamorro et al. 2015; Garcia-Fernandez et al. 2020). Cellular endpoints such as apoptosis, mitochondrial integrity, and oxidative stress levels can be studied to better understand the impact of nanoparticles on humans, thereby contributing to a reduction of animal sacrifices. Human Caco-2 and HepaRG cells can serve as suitable cell models for the intestinal wall and the liver, respectively (Artursson and Karlsson 1991; Gripon, Rumin et al. 2002). HepaRG cells differentiate into biliary-like and hepatocyte-like cells when treated with dimethyl sulfoxide (DMSO) for 2 weeks (Cerec et al. 2007). Caco-2 cells, originally derived from a colon carcinoma, differentiate during 3 weeks into an intact enterocyte-like cell layer, including tight junctions and microvilli (Artursson and Karlsson 1991; Lichtenstein et al. 2016). Caco-2 cells can be used in transwell systems to imitate the intestinal barrier and investigate uptake and transport mechanisms in the intestine.

When nanoparticles interact with cells of the body, they may alter their homeostasis on various levels. It has been shown that iron oxide nanoparticles can impair cellular homeostasis (Wu et al. 2010; Cromer Berman et al. 2013; Strugari et al. 2019). However, available data are not coherent and there are still knowledge gaps regarding correlation between physicochemical particle characteristics and cellular effects.

In this work, we studied the intestinal and hepatic effects of four iron oxide nanoparticles, one food pigment sold as E172, and soluble FeSO₄. The kind of nanoparticles used in this study can be found in different E172 pigments, and therefore oral exposure to such particles is likely to occur (Voss et al. 2020a). Ion release was investigated during the digestive cascade as well as in different fluids used in cell culture studies. Uptake and transport at the intestinal barrier were investigated with Caco-2 cells, while hepatic uptake was studied in HepaRG cells. Moreover, various toxicological tests were conducted both in Caco-2 and in HepaRG cells to understand the influence of iron oxide nanoparticles on intestinal and hepatic cells.

Materials and methods

Chemicals and nanoparticles

Chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), Merck (Darmstadt, Germany), or Carl Roth (Karlsruhe, Germany) if not otherwise indicated. The commercial food dye E172 was purchased from a company in the United Kingdom, the brand of the food pigment is known to the authors and available upon request.

Three nanoparticle dispersions were purchase from US Nano (Huston, TX, USA) containing (1) rod-shaped and spherical particles of γ-Fe₂O₃ (15%, orange), (2) rod-shaped particles of α-Fe₂O₃ (20%, red) and spherical particles of Fe₃O₄ (20%, black). Rod-shaped, yellow γ-Fe₂O₃ nanoparticles were obtained from Merck as 20% dispersion. All particles were dispersed freshly at a concentration of 2.56 mg/mL according to the modified NanoGenoTox protocol: Ultrasonication was carried out with a Sonopuls HD 2200 Homogenisor equipped with an apex KE76 (Bandelin, Berlin, Germany) for 5:09 min at 20% amplitude. 15.36 mg E172 was pre-wetted with 60 µL 70% ethanol before addition of water (to a concentration of 2.56 mg/mL) and ultrasonication. For stabilization, BSA was added to all samples to a final concentration of 0.05% immediately after sonication and before use.

Solubility

To assess solubility in different media, all nanoparticles and FeSO₄ were diluted in MilliQ H₂O, and in the cell culture media Dulbecco’s Modified Eagle Medium (DMEM; GE Healthcare, Freiburg, Germany) or William’s E Medium. These media resembled the media used in cell culture assays (see below). Incubation was carried out for 24 h at 37 °C. After that, solutions were ultracentrifuged at 100,000× g and the supernatant was analyzed for iron content. Atomic Absorption Spectroscopy (AAS) operating in iron mode (PinAAcle 900Z, Perkin Elmer, Singapore, the program can be found in the supplementary material, Table S1).

In vitro digestion

Artificial in vitro digestion is an established method to assess the influence of digestive juices on different materials (Kästner et al. 2017; Sieg et al. 2017; Stock et al. 2020; Voss et al. 2020b). It consists of three different artificial digestive juices, namely saliva, gastric, and intestinal fluid; their composition can be found in the supplementary material (Table S2).

All nanoparticles, the E172 food pigment and FeSO₄ were added to the saliva in a concentration of 330 µg Fe/mL. The model resembles the digestion process, adding gastric and intestinal juice subsequently, leading to a dilution of the particles. It started with 16 mL synthetic saliva for 5 min. After that, 10 mL were taken for further analysis. 14 mL of gastric juice were added, and the solution was set to pH 2.0 using hydrochloric acid. After 2 h, another 10 mL was taken, and 10 mL of intestinal fluid was added. The pH was adjusted to...
7.5 using sodium bicarbonate and the mixture was stirred for 2 h. In all stages, the fluids were constantly stirred in a water bath at 37 °C. To ensure enzyme activities in the digestive juices, enzyme activity assays were performed and measured photometrically: amylase activity in saliva was verified using amylpectin azure, the activity of pepsin in gastric juice by an albumin/bromophenol blue complex, lipase activity using 4-methylumbelliferyl oleate, and trypsin activity was confirmed using azocasein as substrates, respectively.

**Cell culture**

HepaRG cells (Biopredic HPR101, St. Gregoire, France) were cultivated according to the recommended protocol using William’s E Medium supplemented with 10% (v/v) FCS, 100 U/mL penicillin and 100 µg/mL streptomycin (P/S), 5 µg/mL insulin and 5 × 10⁻⁵ M hydrocortisone hemisuccinate as published before (Luckert et al. 2017; Sieg et al. 2019) HepaRG cells were cultivated for 2 weeks without supplementing DMSO and for another 2 weeks with supplementing 1.7% DMSO. For incubation, the cells were adjusted to the assay medium with 0.5% DMSO and 2% FCS 2 days prior to incubation. On the day of incubation with nanoparticles, the test substances were diluted in assay medium.

Caco-2 cells (ECACC: 86010202) were obtained from the European Collection of Authenticated Cell Cultures (Salisbury, UK) and cultivated in DMEM with 10% FCS and 105 Units/L penicillin and 100 µg/mL streptomycin. For all assays, Caco-2 cells were differentiated for 21 days.

Both cell lines were kept at 37 °C and 5% CO₂ in a humidified atmosphere. After seeding in the appropriate plate format, cells were fed every 2–3 days. For incubation, cell culture medium was replaced by 100 µL of the different particles suspended in cell-specific phenol red-free medium.

**Uptake and transport**

50,000 Caco-2 cells were seeded in 12-well transwell plates with inserts of 1.12 cm² growth area and a 3 µm pore size polycarbonate membrane (Corning Incorporated, New York City, NY, USA) and differentiated for 3 weeks. Membrane integrity was checked by transepithelial electrical resistance (TEER) with an EVOM2 Electrode (World Precision Instruments, Sarasota, FL, USA). After incubation, the apical and basolateral media were collected, the inserts were washed, and the membrane was cut out for further analysis. All compartments were analyzed by AAS as described above.

HepaRG cells were seeded in 12-well plates and differentiated for 4 weeks as described above. After incubation, the supernatant was collected, and cells were washed with PBS. Cells were trypsinized and collected. Supernatant, wash fractions and cells were analyzed for iron content by AAS as described above.

**Cellular effects**

HepaRG and Caco-2 cells were seeded in 96-well plates at a density of 9000 (Hepa-RG) or 5000 (Caco-2) cells per well. They were cultivated for 4 (HepaRG) or 3 (Caco-2) weeks as described above. Test substances were diluted in the depicted concentrations in appropriate assay medium and cells were incubated for 24 h in a volume of 100 µL. For all assays, color interference was taken into account by measuring wells with particles but without cells and calculating this into the background signal.

Cell viability was assessed using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for mitochondrial function according to the manufacturer’s instructions (Merck, Darmstadt, Germany). 0.01% Triton X-100 served as a positive control. Mitochondrial membrane potential was investigated using the JC-10 assay, which is based on a fluorescent dye that is red in mitochondria but turns green after release into the cytosol due to depolarization of the mitochondrial membrane. 2 h before end of incubation, the positive control 1 mg/mL verapamil was added to the designated cells. After incubation, all media with test substances was replaced with 50 µL of 50 µM verapamil for 15 min. Then, verapamil was removed and 100 µL of 10 µM JC-10 (Santa-Cruz Biotechnologies, Dallas, TX, USA) in phosphate buffered saline (PBS) was added for 30 min (37 °C, 5% CO₂). Cells were washed with PBS twice and measured in 100 µL PBS at ex./em. 490/525 nm and ex./em. 540/590 nm. The 525 nm/590 nm fluorescence ratio was used to determine the membrane potential. The MCB assay was performed to investigate reduced glutathione levels. After 24 h of treatment, the test substances were removed and 250 µL MCB solution (40 µM) was added for 30 min at 37 °C and 5% CO₂. After washing with PBS, cells were lysed with the desorption solution described for MTT and fluorescence was measured (ex./em.380/ 460 nm). Buthionine sulfoximine (BSO) (100 µM) served as a positive control.

All assays were measured on a multi-well plate reader (Tecan, Männedorf, Switzerland).

Activities of caspase 3, caspase 8 and caspase 9 were measured using specific substrates, which are cleaved by the enzymes into fluorescent products. After 24 h of incubation, particles were removed and 50 µL lysis buffer (50 mM HEPES, 2% v/v Triton X-100, pH 7.4) was added. Plates were shaken for 15 min until cell debris was visible. Then, 100 µL of reaction buffer (50 mM HEPES, 5 mM EDTA, 0.1% (v/v) CHAPS, 5% (v/v) glycerin (pH 7.4)) containing 50 µM of the respective substrates and 5 µM dithiothreitol (DTT) was added per well. The substrates were:

- 100 µL of reaction buffer (50 mM HEPES, 5 mM EDTA, 0.1% (v/v) CHAPS, 5% (v/v) glycerin (pH 7.4)) containing 50 µM of the respective substrates and 5 µM dithiothreitol (DTT) was added per well.

The substrates were:

- 100 µL of reaction buffer (50 mM HEPES, 5 mM EDTA, 0.1% (v/v) CHAPS, 5% (v/v) glycerin (pH 7.4)) containing 50 µM of the respective substrates and 5 µM dithiothreitol (DTT) was added per well.

The substrates were:

- 100 µL of reaction buffer (50 mM HEPES, 5 mM EDTA, 0.1% (v/v) CHAPS, 5% (v/v) glycerin (pH 7.4)) containing 50 µM of the respective substrates and 5 µM dithiothreitol (DTT) was added per well.
Ac-DEVD-AFC (caspase 3), Ac-IETD-AFC (caspase 8) and Ac-LEHD-AFC (caspase 9) (all from Cayman Chemical, Ann Arbor, MI, USA). After 5 h, plates were measured at ex./em. 400/505 nm (caspase 9) or at ex./em. 380/500 nm (caspase 3, caspase 8). For Western blotting analysis, cells were differentiated in six-well plates and incubated with iron oxide nanoparticles for 24 h. After that, cells were washed three times with ice-cold PBS containing protease inhibitor cocktails and lysed using RIPA buffer (50 mM Tris–HCl, 150 mM NaCl, 2 μM EGTA, 0.1% (w/v) SDS, 0.5% (w/v) deoxycholic acid) supplemented with protease inhibitor (Roche, Basel, Switzerland). After cell lysis, protein content was assessed with the BSA assay and 20 μg protein was used for Western-Blot analysis. Therefore, a 12% SDS-PAGE was used. Protein transfer was achieved by semi-dry blotting technique. After blotting, the membrane was stained with ponceau red to ensure effective protein transfer and blocked with 5% milk powder in PBS.

Cleaved caspases were detected using primary rabbit antibodies (#9661S, #7237S, #52873, in 1:1000 dilution, Cell signaling Technology, Frankfurt am Main, Germany) and secondary Goat-anti-rabbit HRP (#HAF008, 1:5000 dilution, R&D Systems, Minneapolis, USA). Pan-actin served as loading control and was detected with pan-actin mouse mAb and sheep anti-mouse HRP (#MS-1295-P, 1:1000 dilution, Thermo Fisher Scientific, CA, USA, and #A-014HRP, 1:5000 dilution, Serum Diagnostica, Heidesee, Germany).

To assess the ATP-content of cells, the commercial CellTiter-Glo Luminescent Cell Viability Assay kit from promega (Walldorf, Germany) was used according to the manufacturer’s instructions with 1 μM oligomycin as positive control. To control for interference with the particles, particle-containing assay medium was given in 96-well plates without cells. 100 μl ATP-assay solution was added as well as 1 μM ATP. The luminescence signal was read in 30 min intervals for 5 h. This assay was only done with HepaRG cells, because of interference when Caco-2 cells were used.

**Results**

**Characteristics of nanoparticles**

All nanoparticles were analyzed in detail in our recent publication (Voss et al. 2020c). The results are summarized in Table 1. As in our previous publication, we assigned symbols to each particle: rod-shaped α-Fe₂O₃ is symbolized as a red rod, rod and spherical γ-Fe₂O₃ as an orange rod and sphere, spherical γ-Fe₃O₄ as a yellow rod, and spherical Fe₃O₄ as a black sphere. The E172 pigment in this study has been characterized thoroughly in our previous study (Voss et al. 2020a).
**Solubility of iron oxide nanoparticles**

Ion release was assessed in different media as well as during the individual steps of the in vitro digestion procedure to ensure the suitability of in vitro cell culture experiments with respect to the dissolution behavior of iron oxide nanoparticles. The particles display a low solubility (below 5%) in H2O, Williams’s E, and DMEM medium in concentrations between 50 and 200 µg Fe/mL (see Fig. 1). Only FeSO4 dissolved in H2O to about 100% but was present nearly insoluble in William’s E and DMEM. In DMEM, a slightly higher dissolution was seen for FeSO4 (7.8% at 100 µg Fe/mL) but this was not significantly different from the other samples or the background (cell culture medium only). No significant differences in solubility were found for the range of iron concentration used in this study.

**In vitro digestion**

All particles including the food pigment behaved very similar in the in vitro digestion (Fig. 2). Almost no ion release was observed in the saliva, the stomach, and the intestine (5% or lower). Ion release was calculated with respect to the total number of iron atoms available from the iron oxide nanoparticles. FeSO4 showed dissolution in the acidic stomach to about 60%, but formed particles in the saliva and reformed particles in the intestinal juice. The dissolution behavior of all iron species in the intestinal juice was similar to the dissolution in cell culture medium.

![Fig. 1 Solubility of iron oxide nanoparticles in different media. Iron oxide nanoparticles, E172 and FeSO4 were dispersed in MiliQ H2O, William’s E, and DMEM cell culture medium in concentrations from 50 to 200 µg Fe/mL and incubated for 24 h. Ion release was assessed using ultracentrifugation and iron measurements in the supernatant with AAS. Mean±SD, n=3, statistical analysis was done with one-way ANOVA followed by Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001)](image)

![Fig. 2 Ion release of iron oxide nanoparticles during in vitro digestion. Supernatants of centrifuged samples were analyzed regarding their ionic iron content. Depicted are results for artificial saliva, gastric juice and intestinal juice with 50 µg Fe/mL in the intestinal juice. Mean±SD, n=3, statistical analysis was done with one-way ANOVA followed by Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001)](image)
Uptake and transport

To better understand the interaction of iron oxide nanoparticles with Caco-2 and HepaRG cells, uptake and transport (in case of Caco-2 cells) were investigated. Results are shown in Fig. 3. To assess background iron levels, a medium control was analyzed. Both γ-Fe₂O₃ and the E172 sample showed significantly higher uptake in Caco-2 cells than the medium control. However, the overall uptake was rather low, with 1.41% (rod and spherical γ-Fe₂O₃), 3.83% (rod γ-Fe₂O₃), and 7.53% (E172). Fe₃O₄ showed ca. 4% uptake, but the obtained value was not significantly different from the background. Transport to the basolateral side of the transwell was not detectable for all iron species investigated. On the other hand, HepaRG cells showed a more pronounced uptake of all but the α-Fe₂O₃ particle. However, this was only significant for Fe₂O₃ and E172 with 42.7 and 47.7% uptake, respectively. Of the γ-Fe₂O₃ particles, between 13 and 14% were found in the cellular layer, and 22.7% of iron from FeSO₄ was detected with HepaRG cells.

Cellular effects

Most of the iron oxide nanoparticles, as well as E172 and FeSO₄ showed only minor effects on Caco-2 and HepaRG cells (Figs. 4 and 5). In the MTT assay, cell viability was stable for all test substances up to 200 µg Fe/mL (Fig. 4a). Similarly, the status of reduced glutathione assessed by the MCB assay did not change remarkably (Fig. 4b). When treated with the two types of γ-Fe₂O₃ particles, the mitochondrial membrane potential of HepaRG cells was impaired at high iron concentrations (Fig. 4c). This effect was not seen in Caco-2 cells. E172 led to a decreased signal ratio in the JC-10 assay in Caco-2 cells, which could indicate a hyperpolarization of the cells. However, since this signal only occurred at 200 µg Fe/mL, where cells are covered with colorful particles, it is not supposed to be a sign of cellular impairment but rather an interference of the particles with the assay. Such an interference has already been seen with other assays and nanoparticles, especially the also used ATP assay here (Zitat Lehmann, https://doi.org/10.1016/j.ab.2016.03.019). Additionally, it is possible that the reagent does not reach the cells sufficiently through the physical barrier. To assess whether the impairment of mitochondrial membrane potential of HepaRG cells after treatment with the γ-Fe₂O₃ particles resulted in decreased ATP-levels, ATP contents in HepaRG cells were assessed. The ATP content of HepaRG cells was stable up to 200 µg Fe/mL with all tested substances. Only FeSO₄ led to a small but insignificant decrease at 200 µg Fe/mL (supplementary material, Figure S1).

Increased activity of the executioner caspase 3 was found in HepaRG cells only, and only after treatment with the spherical and rod-shaped γ-Fe₂O₃ and the Fe₂O₃ particles (Fig. 5a). The decreased activity of caspase-3 in Caco-2 cells (around 80%) after treatment with FeSO₄, the rod and spherically shaped γ-Fe₂O₃ and E172 at 200 µg Fe/mL was statistically significant. However, this decrease is probably due to interference of the high amounts of particles with the assay. In this concentration, the cells are covered in particles and it is very difficult to transfer aliquots without particles to the measurement plate. The same is true for Fe₂O₃ in Caco-2 cells and α-Fe₂O₃ particles in HepaRG cells. Therefore, the activity of the upstream caspases 8 and 9 was only assessed in HepaRG cells with spherical and rod-shaped γ-Fe₂O₃ and the Fe₂O₃ particles (Fig. 5b, c). There, an increase was shown for caspase 9 activity at high concentrations (100 and 200 µg FeSO₄).

---

![Fig. 3](image-url)  
Fig. 3 Uptake and transport of iron oxide nanoparticles in Caco-2 and HepaRG cells. For Caco-2 cells, uptake and transport could be assessed using a transwell system. Therefore, differentiated Caco-2 cells were treated with 50 µg Fe/mL for 24 h. Cells were washed and the membrane was collected for uptake analysis while the iron content in the basolateral compartment indicated transport. Cells were differentiated in a 12-well system and treated with 50 µg Fe/mL for 24 h. After that, the cell layer and the supernatant were analyzed for iron content separately. For HepaRG cells, only iron uptake was investigated. The red dashed line indicates the background resulting from the iron content in the medium control plus the limit of quantification. Mean ± SD, n = 3, statistical analysis was done with one-way ANOVA followed by Dunnett’s test (*p < 0.05, **p < 0.01, ***p < 0.001)
Fe/mL) after treatment with spherical and rod-shaped γ-Fe₂O₃, Fe₃O₄ led also to a slight increase, but this was not significant. Western blot analysis of cleaved caspases confirmed these results (Fig. 5d, e).

In the same manner, the ratio of apoptotic and necrotic cells did not change significantly for HepaRG and Caco-2 cells when treated with 50, 100, and 200 µg Fe/mL (see supplementary material, Figure S2). Also, anti-apoptotic genes rather than pro-apoptotic genes were upregulated.
especially BCL-2 in HepaRG cells (see supplementary material, Figure S3).

Discussion

Even though nanoparticle use has increased in the twenty-first century, risk assessment of these materials is still difficult. As for most nanoparticles, data for risk evaluation of iron oxide nanoparticles are incomplete. Knowledge gaps exist especially regarding the interaction with the gastrointestinal and hepatic system.
Iron oxides are almost insoluble in water and at neutral pH (Cornell 2003). However, it was not known how they interact with the solutions of the gastrointestinal tract, where especially the acidic stomach juice could lead to higher ion release. Here, we showed that iron oxide nanoparticles remain mostly unaltered by the digestive fluids. This is different to other nanoparticles investigated with the in vitro digestion system (Böhmert et al. 2014; Stock et al. 2020; Voss et al. 2020b). Since iron oxide nanoparticles show similar physicochemical properties in the simulated digestive fluid and in tested cell culture media, in vitro cell culture studies are suitable to study the cellular effects of the particles. This is also true for soluble FeSO₄, even though it dissolved completely in the acidic stomach juice. In the final stage of the in vitro digestive cascade, the intestinal fluid, FeSO₄ showed a de novo formation of particles, similar to the behavior in DMEM and William’s E medium.

The Caco-2 transwell system provides an in vitro model to determine uptake and transport of xenobiotics at the intestinal barrier. Here, it was shown that iron oxide nanoparticles are taken up to small extent by Caco-2 cells, whereas no transport to the basolateral department was detected. This has also been shown by others using the Caco-2 transwell system either in monoculture or in combination with HT-29-MTX or goblet cells (Kenzaoui et al. 2012; Strugari et al. 2019). However, increased iron levels in spleen and liver were found after oral exposure to iron oxide nanoparticles in vivo studies, indicating that some particles can cross the intestinal barrier (Singh et al. 2013; Chamorro et al. 2015; Garcia-Fernandez et al. 2020). This discrepancy may be due to the morphology of the Caco-2 cell model, which shows stronger tight junctions than the intestinal barrier in vivo (Hilgendorf et al. 2000). Moreover, the intestinal barrier is composed of different cell types. Co-culture models aim to better understand their interaction.

In all assays. However, even though the rod-shaped γ-Fe₂O₃ particle impaired mitochondrial membrane potential, no effect was seen on the ATP level. This is in line with results from Barlati et al. who treated male Wistar rats with increasing concentrations of iron oxide nanoparticles and did not detect any changes in mitochondrial respiratory chain complex activities and coupling (Barlati et al. 2013). Moreover, also Hussain et al. did not see any changes in mitochondrial membrane potential after treatment of BRL 3A rat liver cells with up to 50 µg Fe/mL (Hussain et al. 2005). In the same manner, Fe₃O₄ and the rod- and spherically shaped Fe₂O₃ particle induced caspase 3 and 9 activities, increasing intrinsic apoptosis, but neither cell viability nor the ratio of apoptotic, necrotic, and viable cells, as determined by flow cytometry analysis, were altered (supplementary material,
Figure S2). It has to be noted, that here, only one time point was investigated (24 h) and that apoptotic events could be initialized after that. However, in our previous study we did not see any changes in cell viability even after 48 h of exposure (Voss et al. 2020c). Moreover, the FACS-results and the gene expression analysis do not indicate signs of early apoptosis (supplementary material, Figure S2 and S3). Similar results have been reported by Zhu et al. (2010). Even though these authors reported different cellular effects like impaired membrane potential and increased ROS levels, the cytotoxic effects were still minor. When we increased the incubation time to 48 h, we still did not observe any cytotoxic effects (Voss et al. 2020c). The results of the qRT-PCR suggest that treatment with nanoparticles leads to an upregulation of anti-apoptotic genes such as BCL-2 and a downregulation of pro-apoptotic genes such as BAD and DIABOLO (see supplementary material, Figure S3). This could prevent increased cell death despite slightly increased caspase activity. However, the exact mechanisms, how some iron oxide nanoparticles lead to cellular impairment is still under investigation and more research is needed to understand how they interfere with the cellular machinery.

**Conclusion**

In summary, we showed that iron oxide nanoparticles interact differently with HepaRG and Caco-2 cells. While there was almost no uptake or transport in Caco-2 cells, the interactions with HepaRG cells were very strong for some particles. Overall, the intestinal Caco-2 cells were impaired only slightly by all investigated iron oxide nanoparticles. Even though HepaRG cells showed higher caspase activities after treatment with two tested particles, no significant increase of cytotoxicity could be detected, suggesting anti-apoptotic cross signaling. For the minor effects observed, no clear dependency on size, shape or chemical structure could be drawn, in line with our previous findings. These results emphasize the difficulty of grouping approaches in nanotoxicology and suggest case-by-case approaches in risk assessment of iron oxide nanoparticles.

**Acknowledgements** We would like to thank Petra Fengler and Jana Hildebrandt for assistance with the artificial digestion.

**Author contributions** LV, AB, LB, and HS were responsible for the conceptualization of the present study. LV and EH acquired and evaluated the data for caspase activities, gene expression and the flow cytometry analysis. LV and VS conducted the MTT assay. LV acquired and evaluated the solubility studies, the in vitro digestion, the uptake and transport studies as well as the JC10, ATP, and MCB assays. The in vitro digestion procedure was established in the laboratory of AFT. LV created the first draft. All authors have given approval to the final version of the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Federal Institute for Risk Assessment (project 1323-102).

**Compliance with ethical standards**

**Conflict of interest** The authors declare no conflict of interest.

**Ethical standards** The manuscript does not contain clinical studies or patient data.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

Artursson P, Karlsson J (1991) Correlation between oral-drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880–885

Baratli Y, Charles AL, Wolff V, Ben Tahar L, Smiri L, Bouitbir J, Zoll J, Piguard F, Tebourbi O, Sakly M, Abdelmelek H, Geny B (2013) Impact of iron oxide nanoparticles on brain, heart, lung, liver and kidneys mitochondrial respiratory chain complexes activities and coupling. Toxicol In Vitro 27(8):2142–2148

Böhmert L, Girod M, Hansen U, Maul R, Knappe P, Nienmann B, Weindner SM, Thünemann AF, Lampen A (2014) Analytically monitored digestion of silver nanoparticles and their toxicity on human intestinal cells. Nanotoxicology 8(6):631–642

Briley-Saebo K, Björnerud A, Grant D, Ahsstrom H, Berg T, Kindberg GM (2004) Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 316(3):315–323

Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Grippon P, Kremsdorf D, Guguen-Guillouzo C, Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45(4):957–967

Chamorro S, Gutierrez L, Vaqueiro MP, Verdoy D, Salas G, Luengo Y, Brenes A, Jose Teran F (2015) Safety assessment of chronic oral exposure to iron oxide nanoparticles. Nanotechnology 26(20):205101

Cornell RMSU (2003) The iron oxides: structure, properties, reactions, occurrences and uses, 2nd edn. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Cromer Berman SM, Kshitiz, Wang CJ, Orukari I, Levchenko A, Bulte JWM, Walczak P (2013) Cell motility of neural stem cells is reduced after SPIO-labeling, which is mitigated after exocytosis. Magn Reson Med 69(1):255–262

Garcia-Fernandez J, Turiel D, Bettmer J, Jakubowski N, Panne U, Riva-Garcia L, Llopis J, SanchezGonzalez C, Montes-Bayon M (2020)
In vitro and in situ experiments to evaluate the biodistribution and cellular toxicity of ultrasmall iron oxide nanoparticles potentially used as oral iron supplements. Nanotoxicology. 14:1–16
Gripp P, Rumín S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guilhouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99(24):15655–15660
Hilgendorf C, Spahn-Languth H, Regardh CG, Lipka E, Amidon GL, Langguth P (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89(1):63–75
Hilty FM, Arnold M, Hilbe M, Teleki A, Knijnenburg JTN, Ehrensperger F, Hurrell RF, Pratsinis SE, Langhans W, Zimmermann MB (2010) Iron from nanocompounds containing iron and zinc is highly bioavailable in rats without tissue accumulation. Nat Nanotechnol 5(5):374–380
Hosny KM, Banjar ZM, Hariri AH, Hassan AH (2015) Solid lipid nanoparticles loaded with iron to overcome barriers for treatment of iron deficiency anemia. Drug Design Dev Therapy 9:313–320
Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ (2005) In vitro and in situ experiments to evaluate the biodistribution and cellular toxicity of ultrasmall iron oxide nanoparticles potentially used as oral iron supplements. Nanotoxicology. 14:1–16
Kästner C, Lichtenstein D, Lampen A, Thünemann AF (2017) Monitoring the fate of small silver nanoparticles during artificial digestion. Colloids Surf A Physicochem Eng Asp 526:76–81
Kenzaoui BH, Vila MR, Miquel JM, Cengelli F, Juillerat-Jeanneret L (2012) Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomed 7:1275–1286
Khalid MK, Asad M, Henrich-Noack P, Sokolov M, Hintz W, Gribartzik L, Zhang E, Dityatev A, van Wachem B, Sabel BA (2018) Evaluation of toxicity and neural uptake in vitro and in vivo of superparamagnetic iron oxide nanoparticles. Int J Mol Sci 19(9):2613
Levy M, Luciani N, Alloypeau D, Elgrably D, Deveaux V, Pechoux C, Chat S, Wang G, Vats N, Gendron F, Factor C, Lotersztajn S, Luciani A, Wilhelm C, Gazeau F (2011) Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials 32(16):3988–3999
Lichtenstein D, Meyer T, Böhmert L, Thünemann AF, Estrela-Lopis I, Braeunung A, Lampen A (2016) Quantification of cellular uptake of silver nanoparticles in intestinal cell models of various complexities. Naunyn-Schmiedebergs Arch Pharmacol 389(1):S20–S20
Siegl H, Kästner C, Krause B, Meyer T, Burel A, Böhmert L, Lichtenstein D, Jungnickel H, Tentscher J, Laux P, Braeunung A, Estrela-Lopis I, Gauffre F, Fessard V, Meijer J, Luch A, Thünemann AF, Lampen A (2017) Impact of an artificial digestion procedure on aluminum-containing nanomaterials. Langmuir 33(40):10726–10735
Singh SP, Rahman MF, Murty US, Mahboob M, Grover P (2013) Comparative study of genotoxicity and tissue distribution of nano and micron sized iron oxide in rats after acute oral treatment. Toxicol Appl Pharmacol 266(1):56–66
Soto K, Garza KM, Murr LE (2007) Cytotoxic effects of aggregated nanomaterials. Acta Biomater 3(3):351–358
Stock V, Fahrenson C, Thuenemann A, Donmez MH, Voss L, Böhmert L, Braeunung A, Lampen A, Sieg H (2020) Impact of artificial digestion on the sizes and shapes of microparticle particles. Food Chem Toxicol 135:111010
Strugari AFG, Stan MS, Gharbia S, Hermenean A, Dinischiotu A (2019) Characterization of nanoparticle intestinal transport using in vitro co-culture model. Nanomaterials 9(1):5
Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ (2015) Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS ONE 10(2):e0117383
Vangijzegem T, Stanicki D, Laurent S (2019) Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv 16(1):69–78
Voss L, Hsiao IL, Ebisch M, Vidmar J, Dreiack N, Böhmert L, Stock V, Braeunung A, Loescher K, Laux P, Thünemann AF, Lampen A, Sieg H (2020a) The presence of iron oxide nanoparticles in the food pigment E172. Food Chem 327:127000
Voss L, Saloga PEJ, Stock V, Böhmert L, Braeunung A, Thünemann AF, Lampen A, Sieg H (2020b) Environmental impact of ZnO nanoparticles evaluated by in vitro simulated digestion (vol 3, pg 724, 2020). ACS Appl Nano Mater 3(5):4914–4914
Voss L, Yilmaz K, Burkard L, Vidmar J, Stock V, Hoffmann U, Potz O, Hammer HS, Peiser M, Braeunung A, Loschner K, Böhmert L, Sieg H (2020c) Impact of iron oxide nanoparticles on xenobiotic metabolism in HepaRG cells. Arch Toxicol 94:4023–4035
Wu XY, Tan YB, Mao H, Zhang MM (2010) Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomed 5:385–399
Zanella D, Bossi E, Gornati R, Bastos C, Faria N, Bernardini G (2017) Nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv 16(1):69–78
Zhu MT, Wang Y, Feng WY, Wang B, Wang M, Ouyang H, Chai ZF (2010) Characterization of nanoparticle intestinal transport using in vitro co-culture model. Nanomaterials 9(1):5
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.